AUS
NZ
UK
CA
USA
IND
Highlights
ResMed (ASX:RMD) has been pressured by concerns that GLP-1 drugs could reduce sleep apnoea device demand.
Real-world evidence suggests patients often use GLP-1 therapies alongside CPAP treatment.
Sentiment across ASX healthcare is shifting as fears are reassessed against actual clinical behaviour.
ResMed has been pressured by GLP-1 fears, but real-world data shows combined therapy use is common. This challenges disruption concerns and reshapes sentiment across ASX healthcare stocks in 2026.
ResMed (ASX:RMD) has become one of the most closely watched names in the Australian share market debate around GLP-1 weight-loss drugs, with its share price movement reflecting shifting expectations rather than just operational performance. Within the ASX 200, the healthcare giant sits at the centre of a broader question: are new obesity treatments reshaping demand for sleep apnoea devices, or is the market overestimating the disruption? The discussion has pulled in investors across ASX healthcare stocks, as narratives around new pharmaceutical breakthroughs collide with long-established medical device usage patterns. What is becoming clearer is that the relationship between the two treatments may be more complementary than competitive.
The Fear That Pressured ResMed
The central concern around ResMed has been straightforward. GLP-1 therapies are designed to support weight loss, and excess weight is one of the strongest drivers of obstructive sleep apnoea, the condition treated by ResMed’s CPAP devices. On a surface level, it appears logical that widespread adoption of weight-loss drugs could reduce the number of patients requiring long-term CPAP therapy. That expectation has weighed heavily on sentiment, driving a re-rating of the stock through 2026. However, the simplicity of that narrative is being tested by emerging clinical patterns and real-world usage data.
Real-World Use Shows a Different Pattern
Early real-world evidence suggests that GLP-1 therapies and CPAP devices are not operating as substitutes in most cases. Instead, patients are often using both treatments simultaneously. This combination approach reflects the complexity of sleep apnoea, which is influenced by multiple physiological and lifestyle factors beyond weight alone. For many patients, GLP-1 therapy addresses metabolic health while CPAP continues to manage sleep-related breathing issues. The result is a more nuanced outcome than the market initially priced in. Rather than a straightforward reduction in device demand, treatment overlap may actually support continued usage of CPAP systems.
Sentiment Versus Clinical Reality
The gap between market sentiment and clinical reality has become a defining feature of ResMed’s share price behaviour. Expectations around disruption expanded quickly as GLP-1 drugs gained global attention, but operational data has not shown a proportional decline in demand signals. This disconnect is important for ASX healthcare stocks more broadly, where innovation cycles can quickly reshape narratives before real-world adoption patterns fully emerge. In ResMed’s case, the share price movement reflects a scenario that assumes maximum disruption, while actual usage trends suggest a more balanced interaction between therapies.
ResMed’s Position in ASX Healthcare
ResMed remains one of the most established names in global sleep and respiratory care, with a strong presence across multiple markets. Its devices are widely used in treating obstructive sleep apnoea, a condition with long-term management requirements. Within the broader ASX healthcare sector, ResMed stands out due to its scale and recurring demand model. While other healthcare companies are exposed to pharmaceuticals or episodic treatments, ResMed operates in a space where ongoing device usage plays a central role in patient care. This structural demand base is one reason the GLP-1 debate has become so closely watched by market participants.
Why GLP-1 Drugs Changed the Narrative
GLP-1 therapies introduced a new variable into healthcare market assumptions. Their ability to support weight reduction has wide-ranging implications for conditions linked to obesity, including diabetes and sleep apnoea. This has led to a reassessment of long-term demand assumptions across multiple medical device categories. In ResMed’s case, the concern is not about current demand, but about how future patient numbers might evolve if obesity rates decline meaningfully. However, healthcare adoption rarely follows a single linear path, and overlapping treatments are common in chronic conditions.
The Role of Treatment Overlap
One of the most important insights emerging from patient data is that chronic conditions are rarely treated in isolation. Sleep apnoea, metabolic disorders and cardiovascular risk factors often coexist, requiring multi-layered treatment approaches. In this context, GLP-1 therapies do not necessarily replace CPAP usage. Instead, they may form part of a broader treatment ecosystem where multiple therapies are used together to manage interconnected conditions. This dynamic helps explain why CPAP demand has not shown the sharp decline some market scenarios anticipated.
ASX Healthcare Sentiment Rebalancing
Across ASX healthcare stocks, sentiment has been gradually recalibrating as the initial enthusiasm and concern around GLP-1 drugs settles into a more measured assessment. Companies with exposure to long-term chronic care management have been reassessed based on actual usage trends rather than early-stage assumptions. This shift has helped stabilise expectations across parts of the sector. ResMed sits at the centre of this adjustment, acting as a reference point for how disruptive new therapies are in practice compared to theory.
What Matters for the Outlook
The key variable for ResMed is not whether GLP-1 drugs exist, but how they are integrated into long-term treatment pathways. If combination therapy remains common, CPAP demand may remain structurally supported even as obesity treatment evolves. At the same time, healthcare innovation cycles are ongoing, meaning new data will continue to shape expectations. The interaction between metabolic health and respiratory treatment remains an evolving space. For ASX healthcare stocks, this means the focus is increasingly shifting from headline disruption narratives to real-world clinical outcomes.
A Sector Still Finding Its Balance
ResMed’s experience highlights a broader theme in the healthcare sector: markets often react quickly to innovation, but slower to adjust to how patients actually behave. As more data emerges, the initial extremes of the GLP-1 debate are being replaced by a more nuanced view. Rather than a clear threat or a clear benefit, the reality appears to sit somewhere in between. That middle ground is where long-term outcomes are likely to be defined.
